Life sciences specialist Merchant Opportunities Fund ups stake in Rhythm
After going substantial on 12 June, Merchant Group has increased its equity stake in RHY.ax from 5.02% to 7.01%, purchasing an additional 2,000,000 for $449,561, equating to $0.225 per share.
Biotech investor Merchant Group becomes a substantial holder of RHY
Rhythm Biosciences welcomes leading biotechnology investor Merchant Group as a substantial holder, buying at between $0.18 and 0.21, average 0.1915 (Refer Annexure A). The Merchant Opportunities Fund, which now holds 5,060,000 FPO or 5.02 percent of Rhythm (up from 2,200,000 units as reported on Sprout8 Twitter…
- Infographic: Excellent prognosis: Developments in Colorectal Cancer Testing – What is Likely to Become The Preferred Test For Population Screening (Part 2 of 2)
- Update: Netflix the Sore Tooth in FANG?
- Infographic: Excellent prognosis: A Primer on Cancer Screening – How Early Detection Can Save Lives and Produce Excellent Investment Returns (Part 1 of 2)
- Netflix the Sore Tooth in FANG?
- Life sciences specialist Merchant Opportunities Fund ups stake in Rhythm